The Gym Group's Unlikely Growth Drug: GLP-1 Comes to the Squat Rack
H1 revenue +10% and EBITDA LNR +12%, but the freshest thing on the call is weight-loss medicine — a threat for apparel, a tailwind for gyms.
GYM.L · Earnings Call · 2026-09-09
A new tail: weight-loss drugs as gym demand, not gym risk
The Gym Group's equity story has been stable for a couple of years: strengthen the core, roll out quality sites, return spare cash. What is genuinely new in the 2026 half-year is the elevation of GLP-1 drugs from an abstract market debate to a stated company tailwind. CEO Will Orr: “PwC estimates that approximately 3 million U.K. adults currently use GLP-1s, with that number potentially increasing to 7 million or 13% of the adult population during 2027.” — Will Orr, Chief Executive Officer · 2026-09-09
That framing matters because the market's read on GLP 1 is bifurcated. For a consumer-facing apparel name it is an assortment problem — DXLG this week framed GLP 1 medication adoption as something to market around for tall customers. For a gym operator the direction of the trade may be reversed. Orr notes that “75% of Gym Group personal trainers said they train someone using GLP-1s.” — Will Orr, Chief Executive Officer · 2026-09-09 Luke Tait added the behavioural logic in Q&A: people on GLP-1s want to sustain muscle mass, build habits and, for some, gain the confidence to walk in at all, so the company is “allocat[ing] a bit more space now to strength and to sort of functional training, a little bit less to cardio.” — Luke Tait, Chief Financial Officer · 2026-09-09
The keyword is new for The Gym Group this quarter and lands in the top tier of its own trajectory — that alone is the signal. And the tape is only lukewarm: the market's oral GLP 1 basket (AZN, LLY, MDGL, WST) is up barely a couple of percent over 30 days, so if the gym-adjacent read is right, the equity market has not voted yet.
We are actively evaluating the most responsible, sustainable and profitable way to participate in this new ecosystem.
That is a deliberately unmonetised statement — no partnership announced, no product launched. It is an option, not earnings.
Refurbs — the compounding engine hiding in plain sight
The more tangible half of the story is the acceleration of major refurbishments, which is quietly becoming as important as the new site rollout. The company completed 10 refurbs in 2025, measured them, liked what it saw, and pushed the 2026 programme to 21. Orr: “For this cohort, we have seen strong member feedback, leading to an average of 10% membership growth... the sites are tracking to deliver a 30% return on the refurbishment capital.” — Will Orr, Chief Executive Officer · 2026-09-09
That 30% is the same hurdle management applies to greenfield openings, and the cohort data backs it up: “The 12 sites opened in 2024 are tracking to deliver more than 30% ROIC.” — Luke Tait, Chief Financial Officer · 2026-09-09 The strategic implication is that the mature estate — historically the drag on group returns — now has its own high-return capital line. Management explicitly floats going faster on refurbs if the 30% proves repeatable.
The rest of the P&L held up: revenue of GBP 133.1m (+10%), EBITDA LNR of GBP 30.8m (+12%), adjusted PBT +31% to GBP 6.4m, and free cash flow of GBP 27.7m funding both the rollout and the buyback. Cost pressure is being contained — cost inflation in the like-for-like estate came in at the low end of the 3–4% guided range, helped by a novel peer to peer energy purchasing scheme and commodity rates fixed into late 2028.
Capital return — and the noise this name simply doesn't have
Leverage stayed at 1x against a 2x target, and the GBP 10m buyback is running: “Year to date, we have acquired 3.1 million shares for just under GBP 6 million, an average price of GBP 1.81 per share.” — Luke Tait, Chief Financial Officer · 2026-09-09 With the facility enlarged by GBP 15m to GBP 117m, management conceded on the call that "there's a good chance we would go again next year". For a GBP ~357m market cap, a repeat buyback plus a self-funded 20-gym-a-year programme is a real return-of-capital story.
The contrast with the wider tape is the interesting bit. The market's dominant keyword cluster in recent quarters is Tariff Refund — AEO, ASO, JILL and SIG all cited tariff recoveries this reporting window. The Gym Group mentions tariffs not at all: it is a domestic U.K. operator with no import exposure and no refund windfall. In a tape obsessed with tariff dis-synergies and AI data-centre capex, this is a rare pure-domestic cash compounder — boring, but clean.
Where it does share airtime is marketing. brand awareness is a live theme across retail reporters this week (AEO, DXLG), and The Gym Group spent on unprompted awareness deliberately, watching whether it converts to members. Underneath sits the structural claim of the High value, low-cost segment: U.K. penetration at 17.6%, the segment taking ~80% share between two brands, and PwC lifting the long-run potential headroom to a further 600–850 locations.
The verdict
What changed: GLP-1 entered the vocabulary as an opportunity rather than an existential risk, and refurbs were promoted from maintenance to a 30%-ROIC growth engine alongside new openings. What did not change: the capital allocation discipline, the 1x leverage, and a business that quietly funds its own expansion. Risks are visible but familiar — openings remain heavily back-weighted (management wants a smoother 2027), competitor rollout drags like-for-like volume by 1–2%, and growth is held at roughly 3% like-for-like revenue for the full year.
There is no price tape provided for GYM.L in this context, so we cannot read the market's verdict on the print; the closest anchor is the GBP 1.81 average buyback price management paid. The strategic question for the next twelve months is simple: does the GLP-1 tail become monetisable, or does it stay a PowerPoint tailwind while the refurbs do the actual compounding?